Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Treasury Shares (2016 - 2024)

Historic Treasury Shares for Syndax Pharmaceuticals (SNDX) over the last 6 years, with Q4 2024 value amounting to $1.3 million.

  • Syndax Pharmaceuticals' Treasury Shares rose 15105.83% to $1.3 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.3 million, marking a year-over-year increase of 15105.83%. This contributed to the annual value of $1.3 million for FY2024, which is 15105.83% up from last year.
  • Latest data reveals that Syndax Pharmaceuticals reported Treasury Shares of $1.3 million as of Q4 2024, which was up 15105.83% from $519436.0 recorded in Q4 2023.
  • Over the past 5 years, Syndax Pharmaceuticals' Treasury Shares peaked at $1.3 million during Q4 2024, and registered a low of $18500.0 during Q4 2020.
  • For the 5-year period, Syndax Pharmaceuticals' Treasury Shares averaged around $398619.4, with its median value being $259788.0 (2022).
  • Per our database at Business Quant, Syndax Pharmaceuticals' Treasury Shares surged by 61531.35% in 2021 and then soared by 5288.93% in 2023.
  • Over the past 5 years, Syndax Pharmaceuticals' Treasury Shares (Quarter) stood at $18500.0 in 2020, then skyrocketed by 615.31% to $132333.0 in 2021, then skyrocketed by 69.87% to $224788.0 in 2022, then skyrocketed by 131.08% to $519436.0 in 2023, then soared by 151.06% to $1.3 million in 2024.
  • Its Treasury Shares stands at $1.3 million for Q4 2024, versus $519436.0 for Q4 2023 and $524236.0 for Q3 2023.